No abstract available.
Nocturnal Enuresis*

No abstract available.
Nocturnal Enuresis*

Nocturnal enuresis has been recognized as an adverse effect of clozapine treatment. We reported 3 chronic schizophrenic patients who had showed nocturnal enuresis following clozapine treatment. Oxybutynin hydrochloride on clozapine-induced enuresis was very effective in 3 patients. The dose in our patients was 5 to 10mg/day. This medication was well tolerated. It is suggested that oxybutynin hydrochloride is a effective therapeutic option in clozapine-induced nocturnal enuresis.
Clozapine* ; Enuresis ; Humans ; Nocturnal Enuresis* ; Schizophrenia

The treatment of choice for primary nocturnal enuresis (PNE) in Korea remains imipramine which has proven to be effective in approximately 50 to 80%, but it is an antidepressant with toxic side effects and risk of overdose. Recently desmopressin (DDAVP, 1-desamino-8-Darginine-vasopressin) has been introduced for the treatment and its effect has been promising in many reports. To find the efficacy and safety of intranasal desmopressin, we evaluated the results of therapy in 48 enuretic children (34 boys and 14 girls). Mean age was 9.8 years (range 5-16). All the children were evaluated at least 3 months after the treatment with intranasal desmopressin. The overall response rate was 83.3%. The number of wet night per week before and after intranasal desmopressin treatment was 6.42 and 1.83 nights per week respectively. No side effects were observed. These data shows that the intranasal desmopressin therapy is effective and safe for the treatment of PNE.
Child ; Deamino Arginine Vasopressin* ; Enuresis ; Humans ; Imipramine ; Korea ; Nocturnal Enuresis*

PURPOSE: The aim of this study, to investigate whether there is any association between enuresis in childhood and nocturnal polyuria syndrome (NPS) in adult life. METHODS: The study consisted of thirty five patients with nocturnal polyuria, and thirty five healthy people without nocturnal polyuria in adult life, were asked to assess their enuresis in childhood. RESULTS: There was a history of enuresis in childhood in 18 (51.42%) of 35 of men with nocturnal polyuria and in 4 (11.42%) of 35 without nocturnal polyuria. Enuresis in childhood was significantly more common in men with nocturnal polyuria than without nocturnal polyuria. The difference was significant (P<0.0001). The prevalence of enuresis in the nocturnal polyuria (51.42%) was more than two-fold higher than reported prevalence in general populations. CONCLUSIONS: The results of this study suggest that the history of enuresis in childhood seems to increase the risk of having NPS in adult life. This relationship should be taken into account in the evaluation of men with complaints from NPS in adult life and the possible common pathophysiology should be considered in the treatment planning.
Adult ; Child ; Enuresis ; Humans ; Male ; Nocturnal Enuresis ; Polyuria ; Prevalence

BACKGROUND: We examined the usefulness of urine osmolality, as a predictive factor in the treatment of monosymptomatic nocturnal enuresis (NE) with combination therapy of imipramine and desmopressin. METHODS: From May 2014 to April 2015, 59 monosymptomatic NE patients participated in this study. Early morning urine osmolality was measured at 1 week and 1 day before combination therapy of imipramine and desmopressin, and at 1 week and 2 weeks after therapy. The response to combination therapy was evaluated at 3 months after treatment. The mean period of combination therapy was 6.4+/-4.2 weeks. Therapeutic response was classified as complete (0-1 wet night/week), partial (over 50% reduction of night) and non-responders (less than 50% reduction of night). RESULTS: The cumulative rate of the complete and partial responders was 76.3%. Among the 3 groups, the statistically lowest value of pre-treatment urine osmolality was observed in the complete responder group (p<0.001). Urine osmolality increased in all groups after treatment, however, statistically the greatest difference between pre and post-treatment urine osmolality was observed in the complete responder group (p=0.024). No serious side effects were observed. CONCLUSION: Early morning urine osmolality and change of urine osmolality between pre and post-treatment have predictive values in the response to combined imipramine and desmopressin for treatment of monosymptomatic NE.
Deamino Arginine Vasopressin* ; Enuresis ; Humans ; Imipramine* ; Nocturnal Enuresis* ; Osmolar Concentration*

PURPOSE: To investigate the correlation between functional bladder capacity, first morning urine osmolality, daytime voiding symptoms, and severity of nocturnal enuresis. MATERIALS AND METHODS: We assessed a total of 101 children with nocturnal enuresis (mean age, 7.7+/-2.3 years). Patients were divided into three groups according to the severity of enuresis: (1) one to six episodes per week (46 cases, 45.5%), (2) one episode every day (29 cases, 28.7%), and (3) multiple episodes every day (26 cases, 25.8%). Baseline parameters were obtained from frequency volume charts for 2 days, first morning urine osmolality, and a questionnaire for the presence of frequency, urgency, and daytime incontinence. RESULTS: The severity of enuresis increased with younger age (p=0.037) and reduced functional bladder capacity (p=0.007) and daytime symptoms of frequency and daytime incontinence (p=0.012, p=0.036). No statistical difference in urine osmolality or urgency was found among the three groups. Both reduced functional bladder capacity and low urine osmolality increased according to the severity of enuresis (p=0.012). CONCLUSIONS: In children with nocturnal enuresis, severity was increased by younger age, reduced functional bladder capacity, and the presence of daytime voiding symptoms of frequency and daytime incontinence. The incidence of small functional bladder capacity was increased in children with everyday wetting, and the incidences of both small functional bladder capacity and low urine osmolality were increased in children with everyday multiple wetting.
Child ; Enuresis ; Humans ; Incidence ; Nocturnal Enuresis ; Osmolar Concentration ; Urinary Bladder

Humans ; Magnetic Resonance Imaging ; Nocturnal Enuresis/diagnostic imaging*

PURPOSE: The aim of the present study was to investigate the effect of single dose imipramine on nocturnal urine output in patients with nocturnal enuresis. METHODS:A total of 6 monosymptomatic enuretic patients of more than 5 years of age were enrolled in this study. We measured nocturnal urine output, urine osrnolality, creatinine clearance, osmolal clearance, excretion rate of solutes, fractional excretion of sodium and potassium, and plasma vasopressin with and without a single oral dose of imipramine(lmg/kg of body weight) at 8 p.m. RESULTS: The administration of imipramine was followed by a significant decrease in noctumal urine output(P=0.02). Urine osmolality was not significantly increased(P>0.05), but osmolal clearance was significantly decreased during imipramine medication(P=0.03). Urinary excretion rate of sodium and potassium showed a statistically insignificant trend toward lower values during imipramine administration in nocturnal enuretics. Fractional urinary excretion of sodium and potassium was significantly decreased during imipramine medication(P<0.05). There was no significant difference in plasma vasopressin level and creatinine clearance in nocturnal enuretics after imipramine. CONCLUSION: Imipramine has a vasopressin independent antidiuretic effect in patients with nocturnal enuresis. The antidiuretic effect of imipramine can be attributed prirnarily to increased a-adrenergic stimulation in the proximal tubules with secondary increased urea and water reabsorption more distally in the nephron. (J Korean Pediatr Soc 2000;43:792 - 797)
Antidiuretic Agents ; Creatinine ; Enuresis ; Humans ; Imipramine* ; Nephrons ; Nocturnal Enuresis* ; Osmolar Concentration ; Plasma ; Potassium ; Sodium ; Urea ; Vasopressins

PURPOSE: To evaluate the effectiveness of a combination of enuresis alarm-desmopressin compared with a desmopressin-based combined pharmacotherapy as the first line in monosymptomatic nocturnal enuresis (MNE). MATERIALS AND METHODS: We evaluated 48 MNE children. Of these, 20 enuretic children were included in the alarm-desmopressin group (AD group) and 28 in the combination pharmacotherapy group (CP group). In the CP group, patients were given desmopressin based combination therapy with imipramine or oxybutynin for 6 months. In the AD group, patients were administered an enuresis alarm associated with an initial 3-month desmopressin combination. The response rates of each therapy were analyzed after 1, 3 and 6 months. After cessation of the 6 month treatment course, the initial and lasting cure rates were analyzed 1 and 6 month later. RESULTS: There was no differentiation in the baseline characteristics and drop-out rates between the two groups during treatment. The mean response rates in the AD and CP groups were 91.8 and 93.7%, respectively. The initial cure rate was higher in the AD (92.3%) than the CP group (52.4%) (p=0.024). The lasting cure rate was also higher in the AD (76.9%) than the CP group (33.3%) (p=0.032). Most of the relapses occurred within 2 month in the CP group and within 4 month in the AD group. CONCLUSIONS: In MNE, a combination of enuresis alarm-desmopressin showed a similar response rate, high initial and lasting cure rates, with a delayed relapse, compared with combination pharmacotherapy. Therefore, a combination of enuresis alarm-desmopressin can be considered a useful tool as the first line in MNE. (Korean J Urol 2005;46:19-24)
Behavior Therapy ; Child ; Deamino Arginine Vasopressin ; Drug Therapy ; Enuresis* ; Humans ; Imipramine ; Nocturnal Enuresis* ; Recurrence